We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $156M
1-Year Est. Return 129.82%
This Fund
S&P 500
This Quarter Est. Return
+14.88%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$132M
AUM Growth
+$8.62M
Cap. Flow
-$414K
Cap. Flow %
-0.31%
Top 10 Hldgs %
86.67%
Holding
29
New
2
Increased
10
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$5.48M
2
TIL icon
Instil Bio
TIL
+$2.47M
3
PMVP icon
PMV Pharmaceuticals
PMVP
+$1.23M
4
KZR
Kezar Life Sciences
KZR
+$973K
5
ADVM
Adverum Biotechnologies
ADVM
+$882K

Top Sells

Rank Stock Value
1
ANTX icon
AN2 Therapeutics
ANTX
+$7.82M
2
WHWK
Whitehawk Therapeutics
WHWK
+$3.36M
3
SAGE
Sage Therapeutics
SAGE
+$1.07M
4
CNTB
Connect Biopharma Holdings
CNTB
+$217K
5
NXTC icon
NextCure
NXTC
+$131K

Sector Composition

Rank Sector Weight
1 Healthcare 97.79%
2 Technology 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NXTC icon
26
NextCure
NXTC
$20.8M
– –
-22,795
Closed -$131K
SAGE
27
DELISTED
Sage Therapeutics
SAGE
– –
-135,095
Closed -$1.07M
WHWK
28
Whitehawk Therapeutics
WHWK
$183M
– –
-1,890,245
Closed -$3.36M
ACHL
29
DELISTED
Achilles Therapeutics
ACHL
– –
-3,804,921
Closed –
1
2

Similar funds

AIS
Accredited Investor Services St. Cloud, Minnesota $156M AUM 21.61% 1-Year Est. Return
BWM
BNB Wealth Management Silver Spring, Maryland $156M AUM
CFG
Cornerstone Financial Group Omaha, Nebraska $156M AUM 12% 1-Year Est. Return
IWA
Invera Wealth Advisors Bend, Oregon $156M AUM 22.76% 1-Year Est. Return
PFO
Pioneer Family Office North Miami Beach, Florida $156M AUM
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return
PMSA
Patrick M. Sweeney & Associates Libertyville, Illinois $156M AUM 19.16% 1-Year Est. Return
GSWA
Good Steward Wealth Advisors Clarksville, Tennessee $156M AUM 13.06% 1-Year Est. Return

BML Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, BML Capital Management held 29 positions worth $132M, up 7% from $124M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

BML Capital Management's Q2 2025 filing shows 2 new, 10 increased, 3 reduced and 5 closed positions. Its largest new stake was Corvus Pharmaceuticals: 118,766 shares worth $475K. The largest sale was AN2 Therapeutics, an estimated $7.82M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Technology.

  • BML Capital Management's largest Q2 2025 buy was Corvus Pharmaceuticals: 118,766 shares worth $475K.
  • BML Capital Management added most to Alumis Inc in Q2 2025, an estimated $5.48M increase.
  • BML Capital Management's biggest Q2 2025 reduction was Connect Biopharma Holdings, cutting an estimated $217K.
  • BML Capital Management fully exited AN2 Therapeutics in Q2 2025, selling an estimated $7.82M.
  • BML Capital Management's ten largest holdings make up 87% of its $132M portfolio in Q2 2025.
  • BML Capital Management opened 2 new positions and closed 5 in Q2 2025.
  • BML Capital Management's portfolio value rose 7% quarter-over-quarter to $132M.

Based on BML Capital Management's 13F filing for Q2 2025, filed 11 Aug 2025.